Beone Medicines LTD. (ONC)
Beone Medicines LTD. reported revenue of $5.34B for the fiscal year ended Dec 31, 2025, up 40.2% from $3.81B the year before. Net income was $286.93M, a net margin of 5.4% (prior year: −$644.79M). At the end of that fiscal year the company reported total assets of $8.19B and shareholders' equity of $4.36B.
Revenue
$5.34B
+40.2% vs prior year
Net income
$286.93M
Net margin 5.4%
Diluted EPS
$0.19
USD per share
Total assets
$8.19B
At Dec 31, 2025
Equity
$4.36B
At Dec 31, 2025
Shares outstanding
1,478M
As of Jul 31, 2026
Explore Beone Medicines LTD.'s filings
- Revenue by year — annual and quarterly revenue with growth rates
- Income statement & cash flow — profit, margins, EPS and operating cash flow
- Balance sheet — assets, liabilities, equity, cash and debt
- SEC filings — 10-K and 10-Q filings with links to EDGAR
Latest SEC filings
- 10-QFiled Aug 5, 2026
- 10-QFiled May 6, 2026
- 10-KFiled Feb 26, 2026
- 10-QFiled Nov 6, 2025
- 10-QFiled Aug 6, 2025
- 10-QFiled May 7, 2025
Source: SEC EDGAR XBRL company facts for CIK 1651308 (raw data). Most recent filing in this dataset: 10-Q filed Aug 5, 2026. SEC data file dated Nov 3, 2026; page built Nov 5, 2026. Figures are as most recently reported, including restatements. How we select figures.